Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$38.18 -2.8%	$37.06	$23.42 ▼ $62.58	$2.28B	0.8	970,122 shs	433,157 shs
CNTA Centessa Pharmaceuticals	$16.56 -0.5%	$15.61	$9.60 ▼ $19.09	$2.23B	1.48	1.09 million shs	389,156 shs
DNLI Denali Therapeutics	$15.65 +0.3%	$14.42	$10.57 ▼ $33.33	$2.28B	1.36	1.80 million shs	1.56 million shs
TRML Tourmaline Bio	$23.03 -2.0%	$19.82	$11.56 ▼ $29.79	$604.15M	2.04	159,153 shs	105,430 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-2.78%	-0.05%	+1.19%	+17.88%	-15.83%
CNTA Centessa Pharmaceuticals	-0.54%	-5.53%	+8.88%	+26.03%	+22.85%
DNLI Denali Therapeutics	+0.32%	+2.76%	+14.99%	+18.74%	-36.15%
TRML Tourmaline Bio	-2.04%	-0.13%	+1.50%	+37.00%	+30.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3604 of 5 stars	3.4	2.0	4.3	3.2	0.8	1.9
CNTA Centessa Pharmaceuticals	2.4804 of 5 stars	3.5	1.0	0.0	2.8	2.5	0.6
DNLI Denali Therapeutics	4.2981 of 5 stars	3.6	1.0	4.7	4.0	3.3	0.0
TRML Tourmaline Bio	1.9939 of 5 stars	3.5	2.0	0.0	1.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	47.55% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$28.10	69.69% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.62	114.79% Upside
TRML Tourmaline Bio	3.00	Buy	$50.14	117.73% Upside

Current Analyst Ratings Breakdown

Latest TRML, CNTA, DNLI, and AGIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $30.00
8/14/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00
8/14/2025	TRML Tourmaline Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00
8/12/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/30/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
7/21/2025	CNTA Centessa Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	60.77	N/A	N/A	$23.57 per share	1.62
CNTA Centessa Pharmaceuticals	$6.85M	323.73	N/A	N/A	$2.58 per share	6.42
DNLI Denali Therapeutics	$330.53M	6.92	N/A	N/A	$7.02 per share	2.23
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$10.09 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.47	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.79	N/A	N/A	N/A	N/A	-40.39%	-29.87%	11/11/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.80	N/A	N/A	N/A	N/A	-40.79%	-36.39%	11/5/2025 (Estimated)
TRML Tourmaline Bio	-$73.21M	-$3.43	N/A	N/A	N/A	N/A	-30.50%	-29.63%	11/6/2025 (Estimated)

Latest TRML, CNTA, DNLI, and AGIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	TRML Tourmaline Bio	-$0.94	-$0.90	+$0.04	-$0.90	N/A	N/A
8/12/2025	Q2 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.38	-$0.03	-$0.38	$0.63 million	N/A
8/11/2025	Q2 2025	DNLI Denali Therapeutics	-$0.74	-$0.72	+$0.02	-$0.72	$5.64 million	N/A
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
CNTA Centessa Pharmaceuticals	0.32	10.11	10.12
DNLI Denali Therapeutics	0.01	10.27	10.27
TRML Tourmaline Bio	N/A	24.68	24.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
CNTA Centessa Pharmaceuticals	82.01%
DNLI Denali Therapeutics	92.92%
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
CNTA Centessa Pharmaceuticals	7.09%
DNLI Denali Therapeutics	12.50%
TRML Tourmaline Bio	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.60 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.91 million	124.42 million	Optionable
DNLI Denali Therapeutics	430	146.21 million	127.94 million	Optionable
TRML Tourmaline Bio	44	25.69 million	22.35 million	Optionable

TRML, CNTA, DNLI, and AGIO Headlines

Recent News About These Companies

EntryPoint Capital LLC Invests $380,000 in Tourmaline Bio, Inc. $TRML

August 23, 2025 | marketbeat.com

Analysts Set Expectations for Tourmaline Bio FY2025 Earnings

August 19, 2025 | marketbeat.com

FY2025 EPS Estimates for Tourmaline Bio Lowered by Analyst

August 19, 2025 | americanbankingnews.com

Tourmaline Bio Q3 EPS Forecast Raised by Leerink Partnrs

August 19, 2025 | marketbeat.com

Lifesci Capital Expects Higher Earnings for Tourmaline Bio

August 19, 2025 | marketbeat.com

What is Wedbush's Forecast for Tourmaline Bio Q3 Earnings?

August 19, 2025 | marketbeat.com

Leerink Partnrs Expects Higher Earnings for Tourmaline Bio

August 19, 2025 | americanbankingnews.com

Tourmaline Bio Q3 EPS Estimate Raised by Lifesci Capital

August 19, 2025 | americanbankingnews.com

Wedbush Estimates Tourmaline Bio's Q3 Earnings (NASDAQ:TRML)

August 18, 2025 | americanbankingnews.com

Tourmaline Bio (NASDAQ:TRML) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

August 17, 2025 | marketbeat.com

Tourmaline Bio (NASDAQ:TRML) Receives "Buy" Rating from Chardan Capital

August 16, 2025 | marketbeat.com

Tourmaline Bio (NASDAQ:TRML) Receives Buy Rating from Guggenheim

August 16, 2025 | marketbeat.com

Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know

August 15, 2025 | zacks.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of "Buy" by Brokerages

August 14, 2025 | marketbeat.com

Tourmaline Bio Reports Positive Trial Results and Strong Cash Position

August 13, 2025 | tipranks.com

Tourmaline Bio, Inc.: Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 13, 2025 | finanznachrichten.de

Tourmaline Bio reports Q2 EPS (90c), consensus (93c)

August 13, 2025 | msn.com

Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 13, 2025 | globenewswire.com

Tourmaline Bio (TRML) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Position Boosted by Federated Hermes Inc.

August 6, 2025 | marketbeat.com

Tourmaline Bio (NASDAQ:TRML) Trading Down 4.6% - Time to Sell?

August 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRML, CNTA, DNLI, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$38.18 -1.09 (-2.78%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$41.45 +3.27 (+8.56%)

As of 05:06 AM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Centessa Pharmaceuticals NASDAQ:CNTA

$16.56 -0.09 (-0.54%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$16.55 -0.01 (-0.06%)

As of 08/28/2025 04:33 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Denali Therapeutics NASDAQ:DNLI

$15.65 +0.05 (+0.32%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$15.17 -0.48 (-3.07%)

As of 04:34 AM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Tourmaline Bio NASDAQ:TRML

$23.03 -0.48 (-2.04%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$23.45 +0.42 (+1.82%)

As of 08/28/2025 07:22 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time